Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer

The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.

Who May Be Eligible (Plain English)

Who May Qualify: - Pancreatic ductal adenocarcinoma - Proven by pathology - Patients who have not received anti-cancer therapies Who Should NOT Join This Trial: - Less than 20 years old - Unable to provide inform and consent - Patients who have active malignancy other than pancreatic adenocarcinoma - Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing - Life expectancy less than 3 months Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Pancreatic ductal adenocarcinoma * Proven by pathology * Patients who have not received anti-cancer therapies Exclusion Criteria: * Less than 20 years old * Unable to provide inform and consent * Patients who have active malignancy other than pancreatic adenocarcinoma * Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing * Life expectancy less than 3 months

Treatments Being Tested

GENETIC

MicroRNA (mir-642b-3p)

A circulating microRNA in the blood of pancreatic cancer patients.

Locations (1)

National Taiwan University Hospital
Taipei, Taiwan